J Clin Neurol.  2017 Jul;13(3):250-258. 10.3988/jcn.2017.13.3.250.

Relationship between Erectile Dysfunction, Comorbidity, and Parkinson's Disease: Evidence from a Population-Based Longitudinal Study

• Yang Y
• Liu H
• Lin T
• Kuo Y
• Hsieh T

• KMID: 2391668
• DOI: http://doi.org/10.3988/jcn.2017.13.3.250

Abstract

BACKGROUND AND PURPOSE
To determine the risk of Parkinson's disease (PD) in relation to erectile dysfunction (ED) based on the National Health Insurance Research Database in Taiwan.
METHODS
We identified 3,153 patients who were newly diagnosed with ED between January 1, 2004 and December 31, 2010. A total of 12,612 randomly selected people without ED served as healthy controls. All of the study subjects were followed-up from the index date to the date of PD diagnosis, withdrawal from the National Health Insurance program, or the end of 2012 whichever occurred first.
RESULTS
The incidence density rate of PD was 1.52-fold higher in the ED cohort than the non-ED cohort (3.44 vs. 1.64 per 1,000 person-years), with an adjusted hazard ratio (HR) of 1.52 [95% confidence interval (CI)=1.09-2.12]. The combined effects on patients with ED and diabetes as well as hypertension showed a significant combined association with the PD risk compared with patients without ED, counterpart comorbidities, or medication use. The adjusted HR of PD for ED was higher for diabetes (2.82, 95% CI=1.42-5.63) and hypertension (2.19, 95% CI = 1.35-3.55).
CONCLUSIONS
ED leads to an increased risk of PD. ED patients with diabetes or hypertension have an elevated risk of PD.

Keyword

comorbidity; diabetes; erectile dysfunction; Parkinson's disease; risk

MeSH Terms

Cohort Studies
Comorbidity*
Diagnosis
Erectile Dysfunction*
Humans
Hypertension
Incidence
Longitudinal Studies*
Male
National Health Programs
Parkinson Disease*
Taiwan

Figure

• 

  Fig. 1 Cumulative incidence of Parkinson's disease estimated using the Kaplan-Meier method for patients with and without ED. ED: erectile dysfunction.

Reference

1. Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013; 381:153–165. PMID: 23040455.

2. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999; 84:50–56. PMID: 10444124.

3. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res. 2000; 12(Suppl 4):S6–S11. PMID: 11035380.

4. Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes. 2013; 6:99–109. PMID: 23300267.

5. Shabsigh R, Shah M, Sand M. Erectile dysfunction and men's health: developing a comorbidity risk calculator. J Sex Med. 2008; 5:1237–1243. PMID: 18439154.

6. Gao X, Chen H, Schwarzschild MA, Glasser DB, Logroscino G, Rimm EB, et al. Erectile function and risk of Parkinson's disease. Am J Epidemiol. 2007; 166:1446–1450. PMID: 17875583.

7. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Genitourinary dysfunction in Parkinson's disease. Mov Disord. 2010; 25:2–12. PMID: 20077468.

8. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol. 2015; 14:57–64. PMID: 25435387.

9. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc. 2005; 104:157–163. PMID: 15818428.

10. Chen CC, Chen LS, Yen MF, Chen HH, Liou HH. Geographic variation in the age- and gender-specific prevalence and incidence of epilepsy: analysis of Taiwanese National Health Insurance-based data. Epilepsia. 2012; 53:283–290. PMID: 22126307.

11. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011; 20:236–242. PMID: 21351304.

12. Hsieh TF, Yang YW, Lee SS, Lin TH, Liu HH, Tsai TH, et al. Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. PLoS One. 2015; 10:e0119694. PMID: 25803433.

13. Yang YW, Hsieh TF, Yu CH, Huang YS, Lee CC, Tsai TH. Zolpidem and the risk of Parkinson's disease: a nationwide population-based study. J Psychiatr Res. 2014; 58:84–88. PMID: 25124550.

14. Chiang TL. Taiwan's 1995 health care reform. Health Policy. 1997; 39:225–239. PMID: 10165463.

15. Tseng CH. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care. 2004; 27:1605–1609. PMID: 15220235.

16. Juan CK, Chen HJ, Shen JL, Kao CH. Lichen simplex chronicus associated with erectile dysfunction: a population-based retrospective cohort study. PLoS One. 2015; 10:e0128869. PMID: 26076496.

17. Yu HH, Chen PC, Yang YH, Wang LC, Lee JH, Lin YT, et al. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study. Atherosclerosis. 2015; 243:11–18. PMID: 26342937.

18. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47:1245–1251. PMID: 7722560.

19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40:373–383. PMID: 3558716.

20. Huang CY, Chou FH, Huang YS, Yang CJ, Su YC, Juang SY, et al. The association between zolpidem and infection in patients with sleep disturbance. J Psychiatr Res. 2014; 54:116–120. PMID: 24721551.

21. Wu YH, Liao YC, Chen YH, Chang MH, Lin CH. Risk of premotor symptoms in patients with newly diagnosed PD: a nationwide, population-based, case-control study in Taiwan. PLoS One. 2015; 10:e0130282. PMID: 26107935.

22. Liu HH, Tsai TH, Lee SS, Kuo YH, Hsieh T. Maximum urine flow rate of less than 15 mL/sec increasing risk of urine retention and prostate surgery among patients with alpha-1 blockers: a 10-year follow up study. PLoS One. 2016; 11:e0160689. PMID: 27513673.

23. Yang YW, Hsieh TF, Lee CC. Reply to the letter by Andrade. J Psychiatr Res. 2015; 60:188–189. PMID: 25444586.

24. Chen YY, Cheng PY, Wu SL, Lai CH. Parkinson's disease and risk of hip fracture: an 8-year follow-up study in Taiwan. Parkinsonism Relat Disord. 2012; 18:506–509. PMID: 22297125.

25. Chen JS, Chang CH, Yang WH, Kao YH. Acute urinary retention increases the risk of complications after transurethral resection of the prostate: a population-based study. BJU Int. 2012; 110(11 Pt C):E896–E901. PMID: 23035623.

26. Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord. 2012; 18:753–758. PMID: 22498320.

27. Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol. 2012; 72:893–901. PMID: 23071076.

28. Sun Y, Chang YH, Chen HF, Su YH, Su HF, Li CY. Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care. 2012; 35:1047–1049. PMID: 22432112.

29. Huang CY, Keller JJ, Sheu JJ, Lin HC. Migraine and erectile dysfunction: evidence from a population-based case-control study. Cephalalgia. 2012; 32:366–372. PMID: 22407657.

30. Smaldone M, Sukkarieh T, Reda A, Khan A. Epilepsy and erectile dysfunction: a review. Seizure. 2004; 13:453–459. PMID: 15324820.

31. Jannini EA, McCabe MP, Salonia A, Montorsi F, Sachs BD. Organic vs. psychogenic? The Manichean diagnosis in sexual medicine. J Sex Med. 2010; 7:1726–1733. PMID: 20537061.

32. Chen YC, Yeh HY, Wu JC, Haschler I, Chen TJ, Wetter T. Taiwan's National Health Insurance Research Database: administrative health care database as study object in bibliometrics. Scientometrics. 2011; 86:365–380.

33. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol. 2003; 2:669–676. PMID: 14572735.

34. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003; 24:197–211. PMID: 12498954.

35. Mikhail N. Does testosterone have a role in erectile function? Am J Med. 2006; 119:373–382. PMID: 16651047.

36. Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch Neurol. 2002; 59:807–811. PMID: 12020264.

37. Okun MS, Walter BL, McDonald WM, Tenover JL, Green J, Juncos JL, et al. Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease. Arch Neurol. 2002; 59:1750–1753. PMID: 12433262.

38. Mitchell E, Thomas D, Burnet R. Testosterone improves motor function in Parkinson's disease. J Clin Neurosci. 2006; 13:133–136. PMID: 16410216.

39. Cunningham RL, Macheda T, Watts LT, Poteet E, Singh M, Roberts JL, et al. Androgens exacerbate motor asymmetry in male rats with unilateral 6-hydroxydopamine lesion. Horm Behav. 2011; 60:617–624. PMID: 21907204.